CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 23 enrolled
Drug / intervention
DEXCOM G6 RT-CGMdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03805412
NCT03805412N/ACompleted

A Pilot Study on the Use of Real-Time Continuous Glucose Monitoring (RT-CGM) as an Educational Tool for Patients With Prediabetes and Diabetes

Nicole Ehrhardt, MD·interventional·Posted Jan 15, 2019·Updated Mar 1, 2023

In Brief

A clinical study evaluating DEXCOM G6 RT-CGM for Diabetes Mellitus, Type 2 and 2 related conditions. Completed, enrolled 23 participants across 1 site.

Detailed Summary

Evaluate the use of brief serial real time continuous monitoring (RT-CGM) as a behavior modification tool in obese patients with prediabetes and diabetes. After receiving RT-CGM, nutrition and exercise education, participants will be able to monitor their blood sugar in real time for 2 sessions . Education on how to interpret CGM in the setting of food choices and exercise coupled with nutrition and exercise information should lead to improved weight and other nutritional and exercise changes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsDexCom, Inc.

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJan 15, 2019
Enrollment StartJan 10, 2019
Primary CompletionJul 3, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.5 years ago

Interventions

DEXCOM G6 RT-CGMdevice

CGM is a way to measure glucose levels in real-time. A tiny electrode called a glucose sensor is inserted under the skin to measure glucose levels in tissue fluid. A small plastic piece of tube remains inserted in the skin. It is connected to a transmitter that sits on top of the skin. It is approved for use on the abdomen for 10 days. It either records the sugars downloaded in the clinic (blinded part of the study) or it sends the information via wireless radio frequency to a monitoring/ display device or to a cellular phone so participants can see data. DEXCOM G6 is FDA approved for use in patients with diabetes and will be used in accordance with instructions as approved for diabetes.